cGMP-specific 3',5'-cyclic phosphodiesterase 6 (PDE6)

cGMP-specific 3',5'-cyclic phosphodiesterase 6 (PDE6) is a critical enzyme in the visual phototransduction cascade, primarily localized in the outer segments of retinal rod and cone photoreceptor cells. It serves as the central effector of the light-activated signaling pathway, where it hydrolyzes cyclic guanosine monophosphate (cGMP) following activation by the G-protein transducin. This rapid reduction in cGMP levels triggers the closure of cGMP-gated ion channels, leading to cell hyperpolarization and the initiation of electrical signals perceived as vision. Structurally, rod PDE6 is a heterotetramer consisting of alpha (PDE6A) and beta (PDE6B) catalytic subunits and two inhibitory gamma (PDE6G) subunits, whereas cone PDE6 is a homodimer of alpha' (PDE6C) subunits with inhibitory gamma' (PDE6H) subunits. Mutations in the genes encoding these subunits are associated with severe inherited retinal diseases, such as retinitis pigmentosa, achromatopsia, and congenital stationary night blindness. PDE6 is also a notable off-target for phosphodiesterase type 5 (PDE5) inhibitors like sildenafil and vardenafil, which can cause transient visual side effects, including blue-tinted vision (cyanopsia) and increased light sensitivity. Current therapeutic research focuses on gene replacement therapies to restore PDE6 function in blind patients and the development of highly selective inhibitors to avoid ocular complications.

Other names

PDE6GMP-PDEPhotoreceptor cGMP-specific 3',5'-cyclic phosphodiesteraseRod cGMP-specific 3',5'-cyclic phosphodiesteraseCone cGMP-specific 3',5'-cyclic phosphodiesterase

Competitive inhibition of the catalytic site of the PDE6 enzyme, which prevents the hydrolysis of cGMP to 5'-GMP, thereby maintaining elevated cGMP levels and keeping cGMP-gated ion channels open.